B. Metzler seel. Sohn & Co. AG Makes New Investment in Biogen Inc. $BIIB

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 12,258 Biogen shares during the second quarter, valued at approximately $2.65 million. Institutional investors and hedge funds collectively own 87.93% of Biogen.
• Analysts maintain a generally positive outlook, with Biogen receiving a “Moderate Buy” consensus rating and an average price target of $227.07. Recent targets range from $215 to $300.
• Biogen reported quarterly earnings of $3.60 per share, exceeding estimates of $2.94, while revenue of $2.74 billion also topped expectations. Revenue increased 3.4% year over year, although earnings declined from $5.47 per share in the prior-year quarter.

B. Metzler seel. Sohn & Co. AG acquired a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 12,258 shares of the biotechnology company's stock, valued at approximately $2,648,000.

Other large investors have also modified their holdings of the company. Rothschild Investment LLC increased its holdings in shares of Biogen by 12.3% in the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company's stock valued at $90,000 after acquiring an additional 56 shares during the period. Meeder Advisory Services Inc. boosted its stake in Biogen by 1.2% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company's stock worth $866,000 after purchasing an additional 57 shares during the period. Kera Capital Partners Inc. boosted its stake in Biogen by 3.5% during the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company's stock worth $316,000 after purchasing an additional 58 shares during the period. Parallel Advisors LLC grew its position in Biogen by 1.5% during the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company's stock worth $801,000 after purchasing an additional 65 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its position in Biogen by 24.4% during the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 66 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BIIB has been the topic of several recent research reports. TD Cowen boosted their price target on Biogen from $215.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Biogen in a research report on Monday, July 13th. Bank of America lowered their target price on Biogen from $217.00 to $215.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 21st. Needham & Company LLC boosted their target price on Biogen from $255.00 to $256.00 and gave the company a "buy" rating in a report on Monday, June 29th. Finally, Oppenheimer restated an "outperform" rating and set a $300.00 price target on shares of Biogen in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Biogen presently has an average rating of "Moderate Buy" and an average target price of $227.07.

Biogen Stock Up 1.1%

BIIB stock opened at $216.78 on Friday. The company has a market cap of $32.03 billion, a P/E ratio of 38.37, a P/E/G ratio of 6.75 and a beta of 0.17. Biogen Inc. has a 52 week low of $131.52 and a 52 week high of $222.15. The company's 50-day moving average price is $205.53 and its 200 day moving average price is $194.48. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period in the prior year, the business posted $5.47 earnings per share. The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, research analysts expect that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source